Genmab A (GMAB) Long-Term Deferred Tax (2019 - 2026)

Genmab A's Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $173.0 million for Q1 2026.

• Quarterly Long-Term Deferred Tax rose 34.11% year-over-year to $173.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.0 million (up 34.11% YoY) and the FY2025 annual result came in at $171.0 million, up 34.65% from the prior year.
• Long-Term Deferred Tax was $173.0 million for Q1 2026 at Genmab A, up from $171.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $173.0 million in Q1 2026 and bottomed at $31.0 million in Q4 2023.
• A 4-year average of $126.4 million and a median of $127.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax soared 309.68% — and 2026, when it surged 34.11%.
• Genmab A's Long-Term Deferred Tax stood at $31.0 million in 2023, then surged by 309.68% to $127.0 million in 2024, then surged by 34.65% to $171.0 million in 2025, then grew by 1.17% to $173.0 million in 2026.
• Business Quant data shows GMAB's Long-Term Deferred Tax at $173.0 million in Q1 2026, $171.0 million in Q4 2025, and $127.0 million in Q3 2025.